Using molecular markers to predict outcome

Journal of Urology

Volumn 172, Issue 5 II, 2004, Pages

  Rubin, Mark A ^a   Kantoff, Philip W ^b   Rosen, Neal ^b   D'Amico, Anthony V ^b   Nelson, Joel B ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

Gene expression; Polymorphism, single nucleotide; Prostate; Prostatic neoplasms; Tumor markers, biological

Indexed keywords

MOLECULAR MARKER; PROSTATE SPECIFIC ANTIGEN;

BIOINFORMATICS; CANCER GROWTH; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; FOLLOW UP; GENE EXPRESSION; HUMAN; MALE; MONITORING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEOMICS; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TECHNOLOGY;

EID: 78649366465     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000142448.58831.d9     Document Type: Conference Paper

References (39)

1. Chu, K. C., Tarone, R. E. and Freeman, H. P.: Trends in prostate cancer mortality among black men and white men in the United States. Cancer, 97: 1507, 2003
2. Weir, H. K., Thun, M. J., Hankey, B. F., Ries, L. A., Howe, H. L., Wingo, P. A. et al: Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst, 95: 1276, 2003
3. Etzioni, R., Penson, D. F., Legler, J. M., Di Tommaso, D., Boer, R., Gann, P. H. et al: Overdiagnosis due to prostate-specific antigen screening: lessons from u.s. Prostate cancer incidence trends. J Natl Cancer Inst, 94: 981, 2002
4. Pound, C. R., Partin, A. W., Eisenberger, M. A., Chan, D. W., Pearson, J. D. and Walsh, P. C.: Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 281: 1591, 1999
5. D'Amico, A. V., Moul, J. W., Carroll, P. R., Sun, L., Lubeck, D. and Chen, M. H.: Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst, 95: 1376, 2003
6. Holmberg, L., Bill-Axelson, A., Helgesen, F., Salo, J., Folmerz, P., Hägmann, M. et al: A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med, 347: 781, 2002
7. Johansson, J. E., Holmberg, L., Johansson, S., Bergstrom, R. and Adami, H. O.: Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA, 277: 467, 1997
8. Johansson, J. E., Adami, H. O., Andersson, S. O., Bergstrom, R., Holmberg, L. and Krusemo, U. B.: High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA, 267: 2191, 1992
9. Johansson, J. E., Andren, O., Andersson, S. O., Dickman, P. W., Holmberg, L., Magnuson, A. et al: Natural history of early, localized prostate cancer. JAMA, 291: 2713, 2004
10. Manson, J. E., Buring, J. E., Satterfield, S. and Hennekens, C. H.: Baseline characteristics of participants in the Physicians' Health Study: a randomized trial of aspirin and beta-carotene in U.S. physicians. Am J Prev Med, 7: 150, 1991
11. Partin, A. W., Kattan, M. W., Subong, E. N., Walsh, P. C., Wojno, K. J., Oesterling, J. E. et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA, 277: 1445, 1997
12. Kattan, M. W., Eastham, J. A., Stapleton, A. M., Wheeler, T. M. and Scardino, P. T.: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst, 90: 766, 1998
13. Kattan, M. W., Zelefsky, M. J., Kupelian, P. A., Scardino, P. T., Fuks, Z. and Leibel, S. A.: Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol, 18: 3352, 2000
14. Kattan, M. W., Potters, L., Blasko, J. C., Beyer, D. C., Fearn, P., Cavanagh, W. et al: Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology, 58: 393, 2001
15. Kattan, M. W., Shariat, S. F., Andrews, B., Zhu, K., Canto, E., Matsumoto, K. et al: The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol, 21: 3573, 2003
16. Rubin, M. A., Mucci, N. R., Manley, S., Sanda, M., Cushenberry, E., Strawderman, M. et al: Predictors of Gleason pattern 4/5 prostate cancer on prostatectomy specimens: can high grade tumor be predicted preoperatively? J Urol, 165: 114, 2001
17. Adam, B. L., Qu, Y., Davis, J. W., Ward, M. D., Clements, M. A., Cazares, L. H. et al: Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res, 62: 3609, 2002
18. Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P. et al: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science, 286: 531, 1999
19. Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I. et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med, 346: 1937, 2002
20. Takahashi, M., Rhodes, D. R., Furge, K. A., Kanayama, H., Kagawa, S., Haab, B. B. et al: Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci USA, 98: 9754, 2001
21. Perou, C. M., Sorlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A. et al: Molecular portraits of human breast tumours. Nature, 406: 747, 2000
22. Luo, J., Duggan, D. J., Chen, Y., Sauvageot, J., Ewing, C. M., Bittner, M. L. et al: Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res, 61: 4683, 2001
23. Magee, J. A., Araki, T., Patil, S., Ehrig, T., True, L., Humphrey, P. A. et al: Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res, 61: 5692, 2001
24. Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K. et al: Delineation of prognostic biomarkers in prostate cancer. Nature, 412: 822, 2001
25. Singh, D., Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C. et al: Gene expression correlates of clinical prostate cancer behavior. Cancer Cell, 1: 203, 2002
26. Welsh, J. B., Sapinoso, L. M., Su, A. I., Kern, S. G., Wang-Rodriguez, J., Moskaluk, C. A. et al: Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res, 61: 5974, 2001
27. Luo, J., Dunn, T., Ewing, C., Sauvageot, J., Chen, Y., Trent, J. et al: Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis. Prostate, 51: 189, 2002
28. Shipp, M.-A., Ross, K.-N., Tamayo, P., Weng, A.-P., Kutok, J.-L., Aguiar, R.-C. T. et al: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med, 8: 68, 2002
29. van't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A., Mao, M. et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415: 530, 2002
30. Lieberfarb, M. E., Lin, M., Lechpammer, M., Li, C., Tanenbaum, D. M., Febbo, P. G. et al: Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Res, 63: 4781, 2003
31. Rhodes, D. R., Barrette, T. R., Rubin, M. A., Ghosh, D. and Chinnaiyan, A. M.: Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res, 62: 4427, 2002
32. Rubin, M. A., Varambally, S., Beroukhim, R., Tomlins, S. A., Rhodes, D. R., Paris, P. L. et al: Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res, 64: 3814, 2004
33. Paweletz, C. P., Charboneau, L., Bichsel, V. E., Simone, N. L., Chen, T., Gillespie, J. W. et al: Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene, 20: 1981, 2001
34. Petricoin, E. F., 3rd, Ornstein, D. K., Paweletz, C. P., Ardekani, A., Hackett, P. S., Hitt, B. A. et al: Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst, 94: 1576, 2002
35. Yasui, Y., Pepe, M., Thompson, M. L., Adam, B. L., Wright, G. L., Jr., Qu, Y. et al: A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. Biostatistics, 4: 449, 2003
36. Simone, N. L., Remaley, A. T., Charboneau, L., Petricoin, E. F., 3rd, Glickman, J. W., Emmert-Buck, M. R. et al: Sensitive immunoassay of tissue cell proteins procured by laser capture microdissection. Am J Pathol, 156: 445, 2000
37. Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D. et al: ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform. Neoplasia, 6: 1, 2004
38. Lin, M., Wei, L. J., Sellers, W. R., Lieberfarb, M., Wong, W. H. and Li, C.: dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics, 2004
39. Harisinghani, M. G., Barentsz, J., Hahn, P. F., Deserno, W. M., Tabatabaei, S., van de Kaa, C. H. et al: Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med, 348: 2491, 2003